<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675841</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-PZFX-201704</org_study_id>
    <nct_id>NCT03675841</nct_id>
  </id_info>
  <brief_title>Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media</brief_title>
  <official_title>A Phase I，Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective To observe the safety and tolerability of Pazufloxacin Mesylate Ear Drops of&#xD;
      different concentrations in patients with simple chronic suppurative otitis media.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The test group was completed in sequence from low to high concentrations, and safety&#xD;
      tolerance was assessed after administration in one concentration group to determine whether&#xD;
      to conduct follow-up group studies and, if necessary, adjust sampling time points according&#xD;
      to pre-experimental results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 29, 2018</start_date>
  <completion_date type="Anticipated">June 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Objective To observe the safety and tolerability of Pazufloxacin Mesylate Ear Drops of different concentrations in patients with simple chronic suppurative otitis media.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under concentration time curve</measure>
    <time_frame>Within two days after administration</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Chronic Suppurative Otitis Media</condition>
  <arm_group>
    <arm_group_label>0.1% single-dose pre</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazufloxacin Mesilate ear drops</intervention_name>
    <description>Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%</description>
    <arm_group_label>0.1% single-dose</arm_group_label>
    <arm_group_label>0.1% single-dose pre</arm_group_label>
    <arm_group_label>0.3% single-dose</arm_group_label>
    <arm_group_label>0.5% single-dose</arm_group_label>
    <other_name>ear drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age is 18-65 years old. Men and women are not restricted.&#xD;
&#xD;
          2. Clinical diagnosis of simple chronic suppurative otitis media with ear effusion&#xD;
             secretion, tympanic membrane perforation about 2 mm, the need for local use of&#xD;
             antibiotics in patients.&#xD;
&#xD;
          3. Voluntarily sign written informed consent.&#xD;
&#xD;
          4. Non-breast-feeding women volunteered to take appropriate contraceptive measures&#xD;
             (including abstinence, intrauterine devices, diaphragms and spermicides) during the&#xD;
             study period (screening period to one week after administration). Men are willing to&#xD;
             use approved contraceptive methods (including the use of condoms and spermicides or&#xD;
             the use of oral, implantable or injectable contraceptives by their partners,&#xD;
             intrauterine devices, diaphragms and spermicides) or sexual partner infertility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Quinolone antibiotics allergy and severe allergic constitution.&#xD;
&#xD;
          2. During the study, ear fluid could not be collected.&#xD;
&#xD;
          3. Patients with severe need for systemic use of antibiotics.&#xD;
&#xD;
          4. Infections caused by pathogens such as fungi and viruses (bullous tympanitis).&#xD;
&#xD;
          5. Patients with cholesteatoma.&#xD;
&#xD;
          6. Complicated with symptoms of extraaural infection (such as periaural cellulitis,&#xD;
             mumps) or intracranial and extracranial complications (such as meningitis, brain&#xD;
             abscess, thrombophlebitis of sigmoid sinus, subperiosteal abscess of the ear, Bezold's&#xD;
             abscess of the neck).&#xD;
&#xD;
          7. Suffer from severe brain, heart, lung, liver, kidney and blood diseases.&#xD;
&#xD;
          8. People suffering from severe diseases that affect their survival, such as malignant&#xD;
             tumors or AIDS, etc.&#xD;
&#xD;
          9. Abnormal liver and kidney function (ALT, Angiotensin sensitivity test(AST) ≥ 1.5 times&#xD;
             the upper limit of normal value), creatinine clearance rate &lt; 60ml/min).&#xD;
&#xD;
         10. Use any local or systemic antibiotics in the first 3 days of the admission.&#xD;
&#xD;
         11. Use any quinolones within the first 7 days of admission.&#xD;
&#xD;
         12. There were smokers who smoked more than 5 cigarettes a day within one year.&#xD;
&#xD;
         13. There was a history of alcoholism and drug abuse within one year.&#xD;
&#xD;
         14. Diagnosis of diabetes or poor blood glucose control.&#xD;
&#xD;
         15. Those who are unable to cooperate or unwilling to cooperate with neuropsychiatric&#xD;
             disorders.&#xD;
&#xD;
         16. Pregnant or lactating women, those who do not use contraceptive measures as required,&#xD;
             or those who are unwilling to take contraceptive measures.&#xD;
&#xD;
         17. Patients who took part in other clinical trials in the first 3 months.&#xD;
&#xD;
         18. Blood donation within three months before admission, or intended during or three&#xD;
             months after the end of the trial or blood components.&#xD;
&#xD;
         19. Researchers believe that patients who are not fit to participate in this clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lei chen, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Province People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lei chen, PHD</last_name>
    <phone>13776620807</phone>
    <email>jspent@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>fen shao, PHD</last_name>
    <phone>13851691161</phone>
    <email>shaofengnj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lei chen, PHD</last_name>
      <phone>13776620807</phone>
      <email>jspent@126.com</email>
    </contact>
    <contact_backup>
      <last_name>fen shao, PHD</last_name>
      <phone>13851691161</phone>
      <email>shaofengnj@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pazufloxacin Mesilate ear drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suppuration</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Otitis Media, Suppurative</mesh_term>
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamide Peroxide</mesh_term>
    <mesh_term>Pazufloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

